{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"39"}]}],"title":"Assessed by Blinded Independent Central Review"},{"categories":[{"measurements":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"44"}]}],"title":"Assessed by Investigator"}],"denoms":[{"counts":[{"groupId":"OG000","value":"299"},{"groupId":"OG001","value":"305"}],"units":"Participants"}],"description":"ORR is defined as the proportion of subjects who achieved a best overall response (BOR) of complete response (CR) or partial response (PR), as assessed by BICR and investigator per RECIST v1.1.","groups":[{"description":"Participants were randomized to receive 6.0 mg/kg of DS-1062a.","id":"OG000","title":"DS-1062a 6.0 mg/kg"},{"description":"Participants were randomized to receive 75 mg/m\\^2 docetaxel.","id":"OG001","title":"Docetaxel 75 mg/m^2"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"From randomization until disease progression or death (whichever occurs first), up to approximately 43 months","title":"Objective Response Rate (ORR) As Assessed by Blinded Independent Central Review (BICR) and Investigator As Per RECIST v1.1 Following DS-1062a Versus Docetaxel","type":"SECONDARY","unitOfMeasure":"Participants"}